Canadian clinical-stage oncology specialist ProNAi Therapeutics Inc has announced the pricing of its initial public offering of common shares on the NASDAQ Global Market. The company, which expects to begin trading under the symbol “DNAI” this week, is seeking US$138 million in proceeds, which is up from its previously-disclosed target. Founded in 2004, ProNAi is focused on developing a new class of therapies through its DNA interference platform for patients with cancer and hematological diseases. In 2014, the Vancouver-based company raised US$59.5 million in Series D financing from mostly U.S. venture capital firms, including Vivo Capital, Frazier Healthcare Ventures and OrbiMed Advisors.
ProNAi Therapeutics Announces Pricing of Initial Public Offering
VANCOUVER, July 15, 2015 /PRNewswire/ – ProNAi Therapeutics, Inc., a clinical-stage oncology company pioneering a novel class of therapeutics based on its proprietary DNAi technology platform, today announced the pricing of its initial public offering of 8,100,000 shares of its common stock at a price to the public of $17.00 per share. The shares are expected to begin trading on The NASDAQ Global Market on July 16, 2015 under the symbol “DNAI.” In addition, the underwriters have been granted a 30-day option to purchase up to an additional 1,215,000 shares of common stock.
Jefferies LLC and BofA Merrill Lynch are acting as joint book-running managers for the offering. BofA Merrill Lynch is also serving as ProNAi’s Strategic IPO Advisor. Wedbush PacGrow and SunTrust Robinson Humphrey are acting as co-managers.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission and was declared effective on July 15, 2015. The offering will be made only by means of a prospectus. A copy of the final prospectus relating to the offering, when available, may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, telephone: (877) 547-6340, email: Prospectus_Department@Jefferies.com; or from BofA Merrill Lynch, Attention: Prospectus Department, 222 Broadway, New York, NY 10038, telephone: (866) 500-5408, email: email@example.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
SOURCE ProNAi Therapeutics Inc.
Photo courtesy of Reuters/Brendan McDermid